Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $1.8 million.

  • Lineage Cell Therapeutics' Cash from Financing Activities rose 6123333.33% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year increase of 10060.24%. This contributed to the annual value of $35.9 million for FY2024, which is 45825.94% up from last year.
  • Lineage Cell Therapeutics' Cash from Financing Activities amounted to $1.8 million in Q3 2025, which was up 6123333.33% from -$307000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Cash from Financing Activities ranged from a high of $21.7 million in Q4 2024 and a low of -$307000.0 during Q2 2025
  • Moreover, its 5-year median value for Cash from Financing Activities was $954000.0 (2021), whereas its average is $4.6 million.
  • In the last 5 years, Lineage Cell Therapeutics' Cash from Financing Activities soared by 140200000.0% in 2024 and then crashed by 39238.1% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Cash from Financing Activities (Quarter) stood at $954000.0 in 2021, then plummeted by 87.21% to $122000.0 in 2022, then plummeted by 110.66% to -$13000.0 in 2023, then skyrocketed by 167284.62% to $21.7 million in 2024, then plummeted by 91.56% to $1.8 million in 2025.
  • Its Cash from Financing Activities was $1.8 million in Q3 2025, compared to -$307000.0 in Q2 2025 and $5.0 million in Q1 2025.